Alliance for Pandemic Preparedness
June 25, 2020
Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019
Category: Article Summary
Topic: Testing and Treatment
- A randomized trial (n=105) evaluated the effect of treatment with the anti-inflammatory agent colchicine in patients with COVID-19. The group receiving colchicine had a lower rate of clinical deterioration (defined as a 2-grade increase on a 7-grade clinical status scale) (OR = 0.11, 95% CI: 0.01-0.96).
- There were no significant differences between treatment and control groups for cardiac outcomes and inflammatory biomarkers.
Deftereos et al. (June 24, 2020). Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2020.13136